|
Abstract: . . . biopharmaceutical production. In addition to its lead anti-IgE immunotherapeutic, Resistentia has initiated pre-clinical development of an immunotherapeutic . . . . . . PRESS RELEASE Uppsala, Sweden, August 30, 2006 Resistentia reports pioneering results from phase I allergy immunotherapy trial . . . . . . RELEASE Uppsala, Sweden, August 30, 2006 Resistentia reports pioneering results from phase I allergy immunotherapy trial . . . . . . profile of the immunotherapy . Here as well, interim data displayed positive results with development of anti-IgE antibodies. The phase I clinical . . . . . . of allergic reactions. The antibodies bind to IgE, thereby blocking it from causing allergic reactions. Such a mechanism of action is efficient . . . . . . Internet: www.resistentia.se VATno. SE556554158701 Preparations for phase II clinical trials in allergic patients continue. For further information, . . . --931,6,78,1388,4655
|